ACE2 and vasoactive peptides: Novel players in cardiovascular/renal remodeling and hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 4, 2015, Pages 217-237

  Mendoza Torres, Evelyn ^a   Oyarzún, Alejandra ^a   Mondaca Ruff, David ^a   Azocar, Andrés ^a   Chiong, Mario ^a   Castro, Pablo F ^b   Jalil, Jorge E ^b   Lavandero, Sergio ^a   Ocaranza, María Paz ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c Biofísica y Bioinformática   (Chile)

Author keywords

ACE2; alamandine; angiotensin (1 7); angiotensin (1 9); blood vessels; heart; hypertension; kidney; renin angiotensin system; tissue remodeling

Indexed keywords

ALAMANDINE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN I (1-9); ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; OLIGOPEPTIDE; PEPTIDE FRAGMENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-9]; BRADYKININ; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; HEPTAPEPTIDE; MAS RECEPTOR; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR REMODELING; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVITY; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RENAL REMODELING; REVIEW; VASCULAR REMODELING;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; MICE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84940841802     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944715597623     Document Type: Review

References (205)

1. Abadir P. Carey R. Siragy H. (2003) Angiotensin AT 2 receptors directly stimulate renal nitric oxide in bradykinin B 2-receptor-null mice. Hypertension 42: 600–604.
2. Abbas A. Gorelik G. Carbini L. Scicli A. (1997) Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 30: 217–221.
3. Ali Q. Patel S. Hussain T. (2015) Angiotensin AT 2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats. Am J Physiol Renal Physiol 308: F1379–F1385.
4. Almeida A. Frábregas B. Madureira M. Santos R. Campagnole-Santos M. Santos R. (2000) Angiotensin-(1-7) potentiates the coronary vasodilatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res 33: 709–713.
5. Averill D. Ishiyama Y. Chappell M. Ferrario C. (2003) Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108: 2141–2146.
6. Bedecs K. Elbaz N. Sutren M. Masson M. Susini C. Strosberg A. et al. (1997) Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 325: 449–454.
7. Benjafield A. Wang W. Morris B. (2004) No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. Am J Hypertens 17: 624–628.
8. Benter I. Yousif M. Anim J. Cojocel C. Diz D. (2006) Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol 290: H684–H691.
9. Berenji K. Drazner M. Rothermel B. Hill J. (2005) Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289: H8–H16.
10. Bosnyak S. Jones E. Christopoulos A. Aguilar M. Thomas W. Widdop R. (2011) Relative affinity of angiotensin peptides and novel ligands at AT 1 and AT 2 Receptors. Clin Sci 121: 297–303.
11. Bosnyak S. Widdop R. Denton K. Jones E. (2012) Differential mechanisms of Ang-(1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens 2012: 192567.
12. Botelho-Santos G. Bader M. Alenina N. Santos R. (2012) Altered regional blood flow distribution in Mas-deficient mice. Ther Adv Cardiovasc Dis 6: 201–211.
13. Brassard P. Amiri F. Schiffrin E. (2005) Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 46: 598–606.
14. Brenner B. Chertow G. (1994) Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171–175.
15. Brenner B. Cooper M. de Zeeuw D. Keane W. Mitch W. Parving H. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869.
16. Brosnihan K. Li P. Ferrario C. (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523–528.
17. Burchill L. Velkoska E. Dean R. Griggs K. Patel S. Burrell L. (2012) Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci 123: 649–658.
18. Burrell L. Harrap S. Velkoska E. Patel S. (2013) The ACE 2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci 124: 65–76.
19. Campbell R. Sui X. Filippatos G. Love T. Wahle C. Sanders P. et al. (2009) Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrol Dial Transplant 24: 186–193.
20. Campese V. (1994) Salt sensitivity in hypertension. renal and cardiovascular implications. Hypertension 23: 531–550.
21. Carvalho M. Duarte F. Faria-Silva R. Fauler B. Da Mata Machado L. de Paula R. et al. (2007) Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic ave 0991 in normotensive rats. Hypertension 50: 762–767.
22. Castro-Moreno P. Pardo J. Hernandez-Munoz R. Lopez-Guerrero J. Del Valle-Mondragon L. Pastelin-Hernandez G. et al. (2012) Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in Shr. Auton Autacoid Pharmacol 32: 61–69.
23. Cha S. Park B. Gao S. Kim S. (2013) Stimulation of ANP by angiotensin-(1-9) via the angiotensin type 2 receptor. Life Sci 93: 934–940.
24. Chamsi-Pasha M. Shao Z. Tang W. (2014) Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep 11: 58–63.
25. Chappell M. Pirro N. Sykes A. Ferrario C. (1998) Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31: 362–367.
26. Chappell M. Tallant E. Brosnihan K. Ferrario C. (1994) Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol 5: 129–137.
27. Clarke W. Bond R. (1998) The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19: 270–276.
28. Coffman T. (2011) Under pressure: the search for the essential mechanisms of hypertension. Nat Med 17: 1402–1409.
29. Collister J. Hendel M. (2003) The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 4:176–179.
30. Crackower M. Sarao R. Oudit G. Yagil C. Kozieradzki I. Scanga S. et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822–828.
31. Creemers E. Pinto Y. (2011) Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89: 265–272.
32. Cunha T. Lima W. Silva M. Souza Santos R. Campagnole-Santos M. Alzamora A. (2013) The nonpeptide Ang-(1-7) mimic AVE 0991 attenuates cardiac remodeling and improves baroreflex sensitivity in renovascular hypertensive rats. Life Sci 92: 266–275.
33. Dandapat A. Hu C. Chen J. Liu Y. Khan J. Remeo F. et al. (2008) Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun 366: 871–877.
34. Dellipizzi A. Hilchey S. Bell-Quilley C. (1994) Natriuretic action of angiotensin (1-7). Br J Pharmacol 111: 1–3.
35. Dias-Peixoto M. Santos R. Gomes E. Alves M. Almeida P. Greco L. et al. (2008) Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52: 542–548.
36. Diez-Freire C. Vazquez J. Correa de Adjounian M. Ferrari M. Yuan L. Silver X. et al. (2006) ACE 2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27: 12–19.
37. Dimitropoulou C. White R. Fuchs L. Zhang H. Catravas J. Carrier G. (2001) Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels. Hypertension 37: 301–307.
38. Dong B. Yu Q. Dai H. Gao Y. Zhou Z. Zhang L. et al. (2012) Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol 59:739–747.
39. Dong X. Han S. Zylka M. Simon M. Anderson D. (2001)A diverse family of GPpCcRrs expressed in specific subsets of nociceptive sensory neurons. Cell 106: 619–632.
40. Donoghue M. Hsieh F. Baronas E. Godbout K. Gosselin M. Stagliano N. et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.Circ Res 87: E1–E9.
41. Donoghue M. Wakimoto H. Maguire C. Acton S. Hales P. Stagliano N. et al. (2003) Heart block, ventricular tachycardia, and sudden death in ACE 2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 35: 1043–1053.
42. Drummer O. Kourtis S. Johnson H. (1990) Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II. Biochem Pharmacol 39: 513–518.
43. Epelman S. Shrestha K. Troughton R. Francis G. Sen S. Klein A. Tang W. (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Failure 15: 565–571.
44. Erdös E. Jackman H. Brovkovych V. Tan F. Deddish P. (2002) Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 34: 1569–1576.
45. Etelvino G. Peluso A. Santos R. (2014) New components of the renin-angiotensin system: alamandine and the Mas-related G protein-coupled receptor D. Curr Hypertens Rep 16: 433.
46. Fan D. Takawale A. Lee J. Kassiri Z. (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5: 15.
47. Faria-Costa G. Leite-Moreira A. Henriques-Coelho T. (2014) Cardivascular effects of the angiotensin type 2 receptor. Rev Port Cardiol 33: 439–449.
48. Fernandes L. Fortes Z. Nigro D. Tostes R. Santos R. Carvalho M. (2001) Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 37: 703–709.
49. Ferrario C. (2003) Commentary on Tikellis et al.: There is more to discover about angiotensin-converting enzyme. Hypertension 41: 390–391.
50. Ferrario C. (2006) Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47: 515–521.
51. Ferrario C. Brosnihan K. Diz D. Jaiswal N. Khosla M. Milsted A. et al. (1991) Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension 18(Suppl. III): III-126–III-133.
52. Ferrario C. Jessup J. Chappell M. Averill D. Brosnihan K. Tallant E. et al. (2005 a) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610.
53. Ferrario C. Jessup J. Gallagher P. Averill D. Brosnihan K. Ann Tallant E. et al. (2005 b)Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189–2196.
54. Ferreira A. Castro C. Guatimosim S. Almeida P. Gomes E. Dias-Peixoto M. et al. (2010) Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusión protein in the heart. Ther Adv Cardiovasc Dis 4: 83–96.
55. Flores-Muñoz M. Godinho B. Almalik A. Nicklin S. (2012 a) Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor.PloS ONE 7: e45564.
56. Flores-Muñoz M. Smith N. Haggerty C. Milligan G. Nicklin S. (2011) Angiotensin 1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 589: 939–951.
57. Flores-Muñoz M. Work L. Douglas K. Denby L. Dominiczak A. Graham D. et al. (2012 b) Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 59: 300–307.
58. Freeman E. Chisolm G. Ferrario C. Tallant E. (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104–108.
59. Funke-Kaiser H. Reinemund J. Steckelings U. Unger T. (2010) Adapter proteins and promoter regulation of the angiotensin AT 2 receptor – implications for cardiac pathophysiology. J Renin Angiotensin Aldosterone Syst 11: 7–17.
60. Gallagher P. Ferrario C. Tallant E. (2008) Regulation of ACE 2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295: H2373–H2379.
61. Gava E. de Castro C. Ferreira A. Colleta H. Melo M. Alenina N. et al. (2012) Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul Pept 175: 30–42.
62. Gembardt F. Grajewski S. Vahl M. Schultheiss H. Walther T. (2008) Angiotensin metabolites can stimulate receptors of the mas-related genes family. Mol Cell Biochem 319: 115–123.
63. Gembardt F. van Veghel R. Coffman T. Schultheiss H. Danser A. Walther T. (2012) Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors. Hypertens Res 35: 547–551.
64. Gibbons G. Dzau V. (1994) The emerging concept of vascular remodeling. N Engl J Med 330: 1431–1438.
65. Gomes E. Santos R. Guatimosim S. (2012) Angiotensin-(1-7)-mediated signaling in cardiomyocytes. Int J Hypertens 2012: 493129.
66. Gorelik G. Carbini L. Scicli A. (1998) Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 286: 403–410.
67. Goulter A. Goddard M. Allen J. Clark K. (2004) ACE 2 gene expression is up-regulated in the human failing heart. BMC Med 2: 19.
68. Greco A. Master R. Fokin A. Jr. Baber S. Kadowitz P. (2006) Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. Can J Physiol Pharmacol 84: 1163–1175.
69. Gurley S. Allred A. Le T. Griffiths R. Mao L. Philip N. et al. (2006) Altered blood pressure responses and normal cardiac phenotype in ACE 2-null mice. J Clin Invest 116: 2218–2225.
70. Guyton A. (1992) Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension 19: I2–I8.
71. Haga S. Tsuchiya H. Hirai T. Hamano T. Mimori A. Ishizaka Y. (2014) A Novel ACE 2 Activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-beta cascades with restored caveolin-1 expression. Exp Lung Res 41:21–31.
72. Hamming I. Kreutz R. Sluimer J. Bolbrinker J. Bernardy C. Walter T. et al. (2005) Renal angiotensin-converting enzyme 2 is unaltered in experimental hypertension. J Am Soc Nephrol 16: TH–PO294.
73. Hamming I. Timens W. Bulthuis M. Lely A. Navis G. van Goor H. (2004) Tissue distribution of ACE 2 protein, the functional receptor for SARS coronavirus. A first step in understanding sars pathogenesis. J Pathol 203: 631–637.
74. Handa R. Ferrario C. Strandhoy J. (1996) Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 270: F141–F147.
75. Hao P. Chen Y. Liu Y. Zhang M. Yang J. Gao F. et al. (2013) Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus. PloS ONE 8: e62788.
76. Haulica I. Bild W. Mihaila C. Ionita T. Boisteanu C. Neagu B. (2003) Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. J Renin Angiotensin Aldosterone Syst 4:124–128.
77. Henrion D. Kubis N. Levy B. (2001) Physiological and pathophysiological functions of the AT 2 subtype receptor of angiotensin II – from large arteries to the microcirculation. Hypertension 38: 1150–1157.
78. Hernandez Prada J. Ferreira A. Katovich M. Shenoy V. Qi Y. Santos R. et al. (2008)Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51: 1312–1317.
79. Heusch G. Libby P. Gersh B. Yellon D. Bohm M. Lopaschuk G. et al. (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383: 1933–1943.
80. Higuchi S. Ohtsu H. Suzuki H. Shirai H. Frank G. Eguchi S. (2007) Angiotensin II signal transduction through the AT 1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417–428.
81. Hilchey S. Bell-Quilley C. (1995) Association between the natriuretic action of angiotensin-(1-7) and selective stimulation of renal prostaglandin I 2 release. Hypertension 25: 1238–1244.
82. Horiuchi M. Akishita M. Dzau V. (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613–621.
83. Horiuchi M. Hayashida W. Kambe T. Yamada T. Dzau V. (1997) Angiotensin type 2 receptor dephosphorylates BCL-2 by activating mitogen-activated protein kinases phosphatase-1 and induces apoptosis. J Biol Chem 272: 19022–19026.
84. Hsueh W. Do Y. Jeyaseelan R. (1998) Angiotensin II and cardiac remodeling. Mt Sinai J Med 65: 104–107.
85. Hu C. Dandapat A. Chen J. Liu Y. Hermonat P. Carey R. et al. (2008) Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 199: 288–294.
86. Huang X. Chen W. Truong L. Lan H. (2003) Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738–1747.
87. Huentelman M. Grobe J. Vazquez J. Stewart J. Mecca A. Katovich M. et al. (2005) Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE 2 in rats. Exp Physiol 90: 783–790.
88. Igase M. Kohara K. Nagai T. Miki T. Ferrario C. (2008) Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 31: 553–559.
89. Igase M. Strawn W. Gallagher P. Geary R. Ferrario C. (2005) Angiotensin II AT 1 receptors regulate ace 2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H1013–H1019.
90. Ishiyama Y. Gallagher P. Averill D. Tallant E. Brosnihan K. Ferrario C. (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 970–976.
91. Iwata M. Silva Enciso J. Greenberg B. (2009) Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. Am J Physiol Cell Physiol 297: C1318–C1329.
92. Jackman H. Massad M. Sekosan M. Tan F. Brovkovych V. Marcic B. et al. (2002) Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A.Hypertension 39: 976–981.
93. Jacob H. (1999) Physiological genetics: application to hypertension research. Clin Exp Pharmacol Physiol 26: 530–535.
94. Jamerson K. Weber M. Bakris G. Dahlof B. Pitt B. Shi V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417–2428.
95. Jin H. Song B. Oudit G. Davidge S. Yu H. Jiang Y. et al. (2012) ACE 2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PloS ONE 7: e38502
96. Johnson H. Kourtis S. Waters J. Drummer O. (1989) Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I. Peptides 10: 489–492.
97. Karram T. Abbasi A. Keidar S. Golomb E. Hochberg I. Winaver J. et al. (2005) Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 289: H1351–H1358.
98. Kaschina E. Unger T. (2003)Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12: 70–88.
99. Kassiri Z. Zhong J. Guo D. Basu R. Wang X. Liu P. et al. (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446–455.
100. Kearney P. Whelton M. Reynolds K. Muntner P. Whelton P. He J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223.
101. Keller G. Zimmer G. Mall G. Ritz E. Amann K. (2003) Nephron number in patients with primary hypertension. N Engl J Med 348: 101–108.
102. Kim M. Yang D. Kida K. Molotkova N. Yeo S. Varki N. et al. (2010) Effects of ACE 2 inhibition in the post-myocardial infarction heart. J Card Fail 16: 777–785.
103. Kloner R. Bolli R. Marban E. Reinlib L. Braunwald E. (1998) Medical and cellular implications of stunning, hibernation, and preconditioning: a NHLBI workshop. Circulation 97: 1848–1867.
104. Koka V. Huang X. Chung A. Wang W. Truong L. Lan H. (2008) Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE 2 via the AT1-ERK/p38 map kinase pathway. Am J Pathol 172: 1174–1183.
105. Kostenis E. Milligan G. Christopoulos A. Sanchez-Ferrer C. Heringer-Walther S. Sexton P. et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806–1813.
106. Krege J. John S. Langenbach L. Hodgin J. Hagaman J. Bachman E. et al. (1995) Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375: 146–148.
107. Lautner R. Villela D. Fraga-Silva R. Silva N. Verano-Braga T. Costa-Fraga F. et al. (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112: 1104–1111.
108. Lely A. Hamming I. van Goor H. Navis G. (2004) Renal ACE 2 expression in human kidney disease. J Pathol 204: 587–593.
109. Lemos V. Silva D. Walther T. Alenina N. Bader M. Santos R. (2005) The endothelium-dependent vasodilator effect of the nonpeptide Ang (1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol 46: 274–279.
110. Li P. Chappell M. Ferrario C. Brosnihan K. (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29: 394–400.
111. Li X. Widdop R. (2004) AT 2 receptor-mediated vasodilatation is unmasked by AT 1 receptor blockade in conscious SHR. Br J Pharmacol 142: 821–830.
112. Li Y. Li X. Yuan H. (2012) Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther 2: 56–62.
113. Loot A. Roks A. Henning R. Tio R. Suurmeijer A. Boomsma F. et al. (2002) Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548–1550.
114. Maia L. Ramos M. Fernandes L. de Carvalho M. Campagnole-Santos M. Souza dos Santos R. (2004) Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 43: 685–691.
115. Mancia G. (2009) Defining blood pressure goals: is it enough to manage total cardiovascular risk? J Hypertens Suppl 27:S3–S8.
116. Marques F. Melo M. Souza L. Irigoyen M. Sinisterra R. de Sousa F. et al. (2012) Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012: 795452.
117. McCollum L. Gallagher P. Tallant E. (2012) Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides 34: 380–388.
118. McKinney C. Fattah C. Loughrey C. Milligan G. Nicklin S. (2014) Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci 126: 815–827.
119. Mehta P. Griendling K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82–C97.
120. Milasta S. Pediani J. Appelbe S. Trim S. Wyatt M. Cox P. et al. (2006) Interactions between the Mas-related receptors Mrg D and MRGE alter signalling and trafficking of Mrg D. Mol Pharmacol 69: 479–491.
121. Miura S. Karnik S. (1999) Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens 17: 397–404.
122. Montezano A. Nguyen Dinh Cat A. Rios F. Touyz R. (2014) Angiotensin II and vascular injury. Curr Hypertens Rep 16: 431.
123. Moon J. (2013) Recent update of renin–angiotensin–aldosterone system in the pathogenesis of hypertension. Electrolyte Blood Press 11: 41–45.
124. Moriguchi A. Tallant E. Matsumura K. Reilly T. Walton H. Ganten D. et al. (1995) Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 25: 1260–1265.
125. Moritani T. Iwai M. Kanno H. Nakaoka H. Iwanami J. Higaki T. et al. (2013) ACE 2 deficiency induced perivascular fibrosis and cardiac hypertrophy during postnatal development in mice. J Am Soc Hypertens 7: 259–266.
126. Nemoto W. Ogata Y. Nakagawasai O. Yaoita F. Tadano T. Tan-No K. (2014) Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p 38 MAPK phosphorylation mediated through spinal Mas receptors in mice. Eur J Pain 18: 1471–1479.
127. Ocaranza M. Godoy I. Jalil J. Varas M. Collantes P. Pinto M. et al. (2006) Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48: 572–578.
128. Ocaranza M. Lavandero S. Jalil J. Moya J. Pinto M. Novoa U. et al. (2010) Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28: 1054–1064.
129. Ocaranza M. Michea L. Chiong M. Lagos C. Lavandero S. Jalil J. (2014 a) Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clin Sci 127: 549–557.
130. Ocaranza M. Michea L. Chiong M. Lavandero S. Jalil J. (2014 b)Reply: dissociating angiotensin 1-9 anticardiovascular remodeling effects from those on blood pressure. J Hypertens 32: 1719–1721.
131. Ocaranza M. Moya J. Barrientos V. Alzamora R. Hevia D. Morales C. et al. (2014 c) Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 32: 771–783.
132. Ocaranza M. Rivera P. Novoa U. Pinto M. Gonzalez L. Chiong M. et al. (2011) Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J Hypertens 29: 706–715.
133. Oliveira M. Fortes Z. Santos R. Kosla M. de Carvalho M. (1999) Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 20: 1195–1201.
134. Oparil S. Sanders C. Haber E. (1970) In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood. Circ Res 26: 591–599.
135. Oparil S. Tregear G. Koerner T. Barnes B. Haber E. (1971) Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog. Circ Res 29: 682–690.
136. Ortiz-Pérez J. Riera M. Bosch X. de Caralt T. Perea R. Pascual J. et al. (2013) Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PloS ONE 8: e61695.
137. Osei S. Ahima R. Minkes R. Weaver J. Khosla M. Kadowitz P. (1993) Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 234: 35–42.
138. Oudit G. Herzenberg A. Kassiri Z. Wong D. Reich H. Khokha R. et al. (2006) Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168: 1808–1820.
139. Oudit G. Liu G. Zhong J. Basu R. Chow F. Zhou J. et al. (2010) Human recombinant ACE 2 reduces the progression of diabetic nephropathy. Diabetes 59: 529–538.
140. Passos-Silva D. Verao-Braga T. Santos R. (2013) Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci 124: 443–456.
141. Patel V. Bodiga S. Basu R. Das S. Wang W. Wang Z. et al. (2012) Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor Axis. Circ Res 110: 1322–1335.
142. Patel V. Clarke N. Wang Z. Fan D. Parajuli N. Basu R. et al. (2014) Angiotensin II Induced Proteolytic cleavage of myocardial ACE 2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 66: 167–176.
143. Paula R. Lima C. Britto R. Campagnole-Santos M. Khosla M. Santos R. (1999) Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides 20: 493–500.
144. Paula R. Lima C. Khosla M. Santos R. (1995) Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26: 1154–1159.
145. Pinheiro S. Simões e Silva A. Sampaio W. de Paula R. Mendes E. Bontempo E. et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490–496.
146. Porsti I. Bara A. Busse R. Hecker M. (1994) Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111: 652–654.
147. Porteri E. Rizzoni D. Piccoli A. Castellano M. Bettoni G. Muiesan M. et al. (1998) Effects of hypotensive and non-hypotensive doses of manidipine on structure, responses to endothelin-1 and ICAM-1 production in mesenteric small resistance arteries of spontaneously hypertensive rats.Blood Press 7: 324–330.
148. Poulter N. (2003) Global risk of cardiovascular disease. Heart 89(Suppl. 2): ii2–ii5.
149. Rabelo L. Xu P. Todiras M. Sampaio W. Buttgereit J. Bader M. et al. (2008) Ablation of angiotensin (1–7) receptor Mas in C 57Bl/6 mice causes endothelial dysfunction. J Am Soc Hypertens 2: 418–424.
150. Rakušan D. Bürgelová M. Vaněčková I. Vaňourková Z. Husková Z. Skaroupková P. et al. (2010) Knockout of angiotensin 1-7 receptor Mas worsens the course of two-kidney, one-clip goldblatt hypertension:roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II.Kidney Blood Press Res 33: 476–488.
151. Ray R. Murdoch C. Wang M. Santos C. Zhang M. Alom-Ruiz S. et al. (2011) Endothelial Nox 4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31:1368–1376.
152. Rentzsch B. Todiras M. Iliescu R. Popova E. Campos L. Oliveira M. et al. (2008) Transgenic angiotensin-converting enzyme 2 overexpression in vessels of shrsp rats reduces blood pressure and improves endothelial function. Hypertension 52: 967–973.
153. Rice G. Thomas D. Grant P. Turner A. Hooper N. (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE 2 and neprilysin in angiotensin peptide metabolism. Biochem J 383: 45–51.
154. Rizzoni D. Porteri E. Bettoni G. Piccoli A. Castellano M. Muiesan M. et al. (1998 a) Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 32: 798–806.
155. Rizzoni D. Porteri E. Piccoli A. Castellano M. Bettoni G. Muiesan M. et al. (1998 b) Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 32: 305–310.
156. Ronco C. Haapio M. House A. Anavekar N. Bellomo R. (2008) Cardiorenal syndrome. J Am Coll Cardiol 52: 1527–1539.
157. Sampaio W. Nascimento A. Santos R. (2003) Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284: 1985–1994.
158. Santos R. Brosnihan K. Chappell M. Pesquero J. Chernicky C. Greene L. et al. (1988) Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 11: I153–I157.
159. Santos R. Brosnihan K. Jacobsen D. DiCorleto P. Ferrario C. (1992)Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19(Suppl.): II-56–II-61.
160. Santos R. Castro C. Gava E. Pinheiro S. Almeida A. Paula R. et al. (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice.Hypertension 47: 996–1002.
161. Santos R. Ferreira A. Nadu A. Braga A. de Almeida A. Campagnole-Santos M. et al. (2004) Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17: 292–299.
162. Santos R. Simoes e Silva A. Maric C. Silva D. Machado R. de Buhr I. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
163. Sasaki S. Higashi Y. Nakagawa K. Matsuura H. Kajiyama G. Oshima T. (2001) Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 38:90–94.
164. Savoia C. Ebrahimian T. He Y. Gratton J. Schiffrin E. Touyz R. (2006) Angiotensin II/AT2 receptor inducedvasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 24: 2417–2422.
165. Savoia C. Tabet F. Yao G. Schiffrin E. Touyz R. (2005) Negative regulation of Rho/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in strokeprone spontaneously hypertensive rats. J Hypertens 23: 1037–1045.
166. Schiffrin E. Park J. Intengan H. Touyz R. (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101: 1653–1659.
167. Shemesh R. Toporik A. Levine Z. Hecht I. Rotman G. Wool A. et al. (2008) Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem 283: 34643–34649.
168. Shi S. Rakugi H. Higashimori K. Jiang B. Higaki J. Mikami H. et al. (1994) Augmentation by converting enzyme inhibition of accelerated endothelin release from rat mesenteric arteries following nephrectomy. Biochem Biophys Res Commun 202: 246–251.
169. Shinohara T. Harada M. Ogi K. Maruyama M. Fujii R. Tanaka H. et al. (2004) Identification of a G protein-coupled receptor specifically responsive to beta-alanine. J Biol Chem 279: 23559–23564.
170. Soares de Moura R. Resende A. Emiliano A. Tano T. Mendes-Ribeiro A. Correia M. et al. (2004) The role of bradykinin, AT 2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol 141: 860–866.
171. Sriramula S. Xia H. Xu P. Lazartigues E. (2014) Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. Hypertension 65:577–86.
172. Stoll M. Cowley A. Jr. Tonellato P. Greene A. Kaldunski M. Roman R. et al. (2001) A genomic-systems biology map for cardiovascular function. Science 294: 1723–1726.
173. Stoll M. Kwitek-Black A. Cowley A. Jr. Harris E. Harrap S. Krieger J. et al. (2000) New target regions for human hypertension via comparative genomics.Genome Res 10: 473–482.
174. Strawn W. Ferrario C. Tallant E. (1999) Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207–211.
175. Suzuki H. Motley E. Frank G. Utsunomiya H. Eguchi S. (2005) Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 3: 305–322.
176. Takahashi S. Mendelsohn M. (2003) Synergistic activation of endothelial nitricoxide synthase (eNOS) by HSP 90 and Akt: calcium-independent eNOS activation involves formation of an HSP 90-Akt-CaM-bound eNOS complex. J Biol Chem 278: 30821–30827.
177. Takeda S. Kadowaki S. Haga T. Takaesu H. Mitaku S. (2002) Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Letters 520: 97–101.
178. Tallant E. Ferrario C. Gallagher P. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 289: H1560–H1566.
179. Tavares F. da Silva I. Gomes D. Barreto-Chaves M. (2013) Angiotensin II type 2 receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion. Cardiovasc Drugs Ther 27: 393–402.
180. Thybo N. Stephens N. Cooper A. Aalkjaer C. Heagerty A. Mulvany M. (1995) Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25: 474–481.
181. Tikellis C. Cooper M. Bialkowski K. Johnston C. Burns W. Lew R. et al. (2006) Developmental expression of ACE 2 in the shr kidney: a role in hypertension? Kidney Int 70: 34–41.
182. Tikellis C. Johnston C. Forbes J. Burns W. Burrell L. Risvanis J. et al. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392–397.
183. Tipnis S. Hooper N. Hyde R. Karran E. Christie G. Turner A. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238–33243.
184. Tom B. de Vries R. Saxena P. Danser A. (2001) Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38: 95–99.
185. Touyz R. (2003) The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 5: 155–164.
186. Touyz R. Schiffrin E. (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639–672.
187. Ueda S. Masumori-Maemoto S. Wada A. Ishii M. Brosnihan K. Umemura S. (2001) Angiotensin (1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens 19: 2001–2009.
188. Varagic J. Ahmad S. Nagata S. Ferrario C. (2014) ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 16: 420.
189. Villela D. Leonhardt J. Patel N. Joseph J. Kirsch S. Hallberg A. et al. (2015) Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci 128: 227–234.
190. Villela D. Passos-Silva D. Santos R. (2014) Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens 23: 130–134.
191. Walters P. Gaspari T. Widdop R. (2005) Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats.Hypertension 45: 960–966.
192. Wang S. Tao T. Fu Z. Xie X. Wang H. Wang Y. (2013) Polymorphisms of angiotensin-converting enzyme 2 gene confer a risk to lone atrial fibrillation in Chinese male patients. Chin Med J (Engl) 126: 4608–4611.
193. Welches W. Brosnihan K. Ferrario C. (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 52: 1461–1480.
194. Welches W. Santos R. Chappell M. Brosnihan K. Greene L. Ferrario C. (1991) Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 9:631–638.
195. WHO (2011) Global status report on noncommunicable diseases 2010. Geneva: World Health Organization: Geneva.
196. Wu K. (2002) Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci 962: 122–130.
197. Xu P. Costa-Goncalves A. Todiras M. Rabelo L. Sampaio W. Moura M. et al. (2008) Endothelial dysfunction and elevated blood pressure in mas gene-deleted mice. Hypertension 51: 547–580.
198. Yagil Y. Yagil C. Crackower M. Jenninger P. (2003) The protective role of ACE 2 in hypertension. Am J Hyper 16: 23A.
199. Yamazato M. Yamazato Y. Sun C. Diez-Freire C. Raizada M. (2007) Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49: 926–931.
200. Yang M. Zhao J. Xing L. Shi L. (2014) The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: a meta-analysis involving 14,122 patients. J Renin Angiotensin Aldosterone Syst DOI: 10.1177/1470320314549221.
201. Ye M. Wysocki J. Naaz P. Salabat M. Lapointe M. Batlle D. (2004) Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43: 1120–1125.
202. Young D. Waitches G. Birchmeier C. Fasano O. Wigler M. (1986) Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45: 711–719.
203. Zheng J. Li G. Chen S. Bihl J. Buck J. Zhu Y. et al. (2014) Activation of the ACE 2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction. Neuroscience 273: 39–51.
204. Zhong J. Huang D. Yang Y. Li Y. Liu G. Song X. et al. (2004) Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 44: 907–912.
205. Zisman L. Keller R. Weaver B. Lin Q. Speth R. Bristow M. et al. (2003) Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE 2. Circulation 108: 1707–1712.